行情

ALT

ALT

Altimmune
NASDAQ

实时行情|Nasdaq Last Sale

2.110
+0.070
+3.43%
已收盘, 16:00 09/20 EDT
开盘
2.020
昨收
2.040
最高
2.140
最低
2.020
成交量
12.05万
成交额
--
52周最高
17.76
52周最低
1.700
市值
4,698.97万
市盈率(TTM)
-0.3966
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALT 新闻

  • Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
  • GlobeNewswire.09/09 12:00
  • 26 Stocks Moving in Thursday's Pre-Market Session
  • Benzinga.09/05 11:44
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.08/21 12:48
  • Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield Clinical Development
  • GlobeNewswire.08/21 12:00

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ALT 简况

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
展开

Webull提供Altimmune Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。